Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-30
2008-03-11
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S201000, C514S202000, C514S206000
Reexamination Certificate
active
07341993
ABSTRACT:
This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 4220761 (1980-09-01), Takaya et al.
patent: 4341775 (1982-07-01), Takaya et al.
patent: 4366153 (1982-12-01), Takaya et al.
patent: 4427677 (1984-01-01), Takaya et al.
patent: 4487767 (1984-12-01), Takaya et al.
patent: 4550102 (1985-10-01), Teraji et al.
patent: 4603129 (1986-07-01), Blumbach et al.
patent: 4647556 (1987-03-01), Lattrell et al.
patent: 4667028 (1987-05-01), Schwab et al.
patent: 4668783 (1987-05-01), Ochiai et al.
patent: 4840945 (1989-06-01), Ohnishi et al.
patent: 4921851 (1990-05-01), Kishimoto et al.
patent: 4943567 (1990-07-01), Nishizawa et al.
patent: 5071979 (1991-12-01), Lattrell et al.
patent: 5693791 (1997-12-01), Truett et al.
patent: 6437119 (2002-08-01), Truett
patent: 6878686 (2005-04-01), Marquess et al.
patent: 6974797 (2005-12-01), Fatheree et al.
patent: 6995138 (2006-02-01), Marquess et al.
patent: 2004/0033939 (2004-02-01), Marquess et al
patent: 2004/0266666 (2004-12-01), Fatheree et al.
patent: 2005/0026818 (2005-02-01), Fatheree et al.
patent: 2 033 377 (1980-05-01), None
patent: 60-41682 (1985-03-01), None
patent: WO 97/41128 (1997-11-01), None
patent: WO 99/42476 (1999-08-01), None
patent: WO 99/64049 (1999-12-01), None
patent: WO 00/39156 (2000-07-01), None
http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=phenylene.
http://en.wikipedia.org/wiki/Substitution—reaction.
http://en.wikipedia.org/wiki/Functional—group.
U.S. Appl. No. 09/457,926, filed Dec. 8, 1999, Christensen et al.
Boeckh, M. et al., “Pharmacokinetics and Serum Bactericidal Activity of Vancomycin Alone and in Combination with Ceftazidime in Healthy Volunteers.” Antibacterial Agents and Chemotherapy, vol. 32. No. 1, pp. 92-95 (1988).
Hammes, W. P., “Biosynthesis of peptidoglycan inGaffkya homari. The mode of action of penicillin G and mecillinam”, Chemical Abstracts, vol. 86, No. 5, Abstract No. 26406 (Jan. 31, 1977).
Kim, M. et al., “Synthesis and Antibacterial Activity of Cephalosporins Having Hydroxamic Acid at C-7 Position.” Biorganic & Med. Chem. Letters, vol. 6, No. 17, pp. 2077-2080 (1996).
Lattrell, R. et al., “Synthesis and Structure-Activity Relationships in the Cefpirome Series.” Journal of Antibiotics, vol. XLI, No. 10, pp. 1374-1394.
Rao, J. et al., “Tight Binding of a Dimeric Derivative of Vancomycin with Dimeric L-Lys-D-Ala-D-Ala.” J. Am. Chem. Soc., vol. 119, pp. 10286-10290 (1997).
Renoud-Grappin, M. et al., “Imidazo[1,5-b]pyridazine-d4T conjugates:synthesis and anti-human Immunodeficiency virus evaluation.” Antiviral Chemistry & Chemotherapy, vol. 9, pp. 205-223.
Staroske, T. et al., “Synthesis of Covalent Head-to-Tail Dimers of Vancomycin.” Tetrahedron Letters 39, pp. 4917-4920 (1998).
Sundram, U. et al., “General and Efficient Method for the Solution- and Solid-Phase Synthesis of Vancomycin Carboxamide Derivatives.” J. Org. Chem., vol. 60, pp. 1102-1103 (1995).
Sundram, U. et al., “Novel Vancomycin Dimers with Activity against VAncomycin-Resistant Enterococci” J. Am. Chem. Soc. , vol. 118, pp. 13107-13108 (1996).
Aggen James
Fatheree Paul R.
Linsell Martin S.
Long Daniel D.
Marquess Daniel
Audet Maury
Hagenah Jeffrey A.
Theravance Inc.
Tsang Cecilia J.
LandOfFree
Cross-linked glycopeptide—cephalosporin antibiotics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cross-linked glycopeptide—cephalosporin antibiotics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cross-linked glycopeptide—cephalosporin antibiotics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965591